Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




MRD Testing Can Identify Breast Cancer Survivors at Higher Risk of Recurrence

By LabMedica International staff writers
Posted on 03 Sep 2025

Breast cancer survival rates continue to improve, but recurrence remains incurable and affects around 30% of patients. More...

Some subtypes, like triple negative and HER2+, relapse within years, while ER+ cancers can recur decades later. Until now, there has been no way to identify survivors harboring dormant cells in real time or to intervene with treatments that could prevent relapse. Now, a new trial shows it is possible to detect these cells and clear them using repurposed drugs.

The trial was conducted by the Abramson Cancer Center of the University of Pennsylvania (Philadelphia, PA, USA) and Penn’s Perelman School of Medicine (Philadelphia, PA, USA). The approach builds on earlier research showing how dormant tumor cells, also known as minimal residual disease (MRD), can persist in patients after treatment. These “sleeper cells” evade imaging tests and may later reactivate, spreading metastatic breast cancer. Researchers identified pathways that allow such cells to survive and targeted them with existing FDA-approved drugs.

In preclinical mouse studies, two drugs that do not work against active cancers were highly effective against MRD, targeting autophagy and mTOR signaling. In the Phase II CLEVER clinical trial, 51 breast cancer survivors were randomized to receive either one of the drugs or both. Dormant tumor cells were cleared in 80% of participants, and after 42 months, only two recurrences were observed. Patients receiving both drugs achieved 100% recurrence-free survival.

The findings, published in Nature Medicine, highlight that treating patients during the sleeper phase may stop cancer from reemerging as metastatic disease. By using existing, affordable drugs, researchers demonstrated a feasible path to preventing relapse in breast cancer survivors. Larger trials, including the ABBY and PALAVY studies, are already underway to confirm and extend the CLEVER trial results. If successful, this strategy could replace “watch and wait” with proactive prevention of recurrence.

“The lingering fear of cancer returning is something that hangs over many breast cancer survivors after they celebrate the end of treatment,” said principal investigator Angela DeMichele, MD, MSCE, FASCO. “Our study shows that preventing recurrence by monitoring and targeting dormant tumor cells is a strategy that holds real promise.”

Related Links:
Abramson Cancer Center of the University of Pennsylvania
Penn’s Perelman School of Medicine


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Collection and Transport System
PurSafe Plus®
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Technology

view channel
Image: The SWITCH hybrid pipette is designed to simplify and accelerate pipetting tasks (Photo courtesy of INTEGRA)

Hybrid Pipette Combines Manual Control with Fast Electronic Aliquoting

Manual pipettes offer the control needed for delicate tasks such as mixing or supernatant removal, but typically fall short in repetitive workflows like aliquoting. Electronic pipettes solve this problem... Read more

Industry

view channel
Image: The partnership between OGT and QIAGEN unlocks a complete sample to report workflow for SureSeq NGS panels (Photo courtesy of OGT)

Qiagen and Oxford Gene Technology Partner on Sequencing Panel Interpretation

In clinical research, next-generation sequencing (NGS) panels provide essential insights for genetic analysis, but many laboratories face challenges in transforming raw sequencing data into clinically... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.